RAPT Therapeutics Inc. (NASDAQ:RAPT) is one of the hot stocks to buy with huge upside potential. On October 21, Wells Fargo raised the firm’s price target on Rapt Therapeutics to $48 from$38 and kept an Overweight rating on the shares. This announcement was made as the firm noted that data from its partner’s CSU (Chronic Spontaneous Urticaria) study suggests that the drug’s efficacy is either comparable to or numerically better than XOLAIR, even when dosed only every 12 weeks. Wells Fargo Boosts RAPT The ...